KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Short term Debt: 2015-2022

Historic Short term Debt for Halozyme Therapeutics (HALO) over the last 8 years, with Dec 2022 value amounting to $13.3 million.

  • Halozyme Therapeutics' Short term Debt was N/A to $710.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $710.7 million, marking a year-over-year change of. This contributed to the annual value of $13.3 million for FY2022, which is 85.09% down from last year.
  • Latest data reveals that Halozyme Therapeutics reported Short term Debt of $13.3 million as of FY2022, which was down 85.09% from $89.4 million recorded in FY2021.
  • Halozyme Therapeutics' 5-year Short term Debt high stood at $397.2 million for FY2020, and its period low was $13.3 million during FY2022.
  • In the last 3 years, Halozyme Therapeutics' Short term Debt had a median value of $89.4 million in 2021 and averaged $166.7 million.
  • Per our database at Business Quant, Halozyme Therapeutics' Short term Debt spiked by 1,932.69% in 2020 and then tumbled by 85.09% in 2022.
  • Yearly analysis of 5 years shows Halozyme Therapeutics' Short term Debt stood at $91.5 million in 2018, then tumbled by 78.64% to $19.5 million in 2019, then soared by 1,932.69% to $397.2 million in 2020, then slumped by 77.49% to $89.4 million in 2021, then plummeted by 85.09% to $13.3 million in 2022.